Cover Image

Performance of large language models on benign prostatic hyperplasia frequently asked questions

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	YuNing Zhang, Yijie Dong, Zihan Mei, Yiqing Hou, Minyan Wei, Yat Hin Yeung, Jiale Xu, Qing Hua, LiMei Lai, Ning Li, ShuJun Xia, Chun Zhou, JianQiao Zhou
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	The Prostate
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Responses to queries concerning “Performance of large language models on benign prostatic hyperplasia frequently asked questions”
by: YuNing Zhang, et al.
Published: (2024)

Minimally invasive surgical therapies for benign prostatic hyperplasia in the geriatric population: A systematic review
by: Ahmad Abid, et al.
Published: (2024)

Link between circadian rhythm and benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS)
by: Dana Cavanaugh, et al.
Published: (2024)

Serum levels of prostate specific antigen, free PSA, [−2]proPSA, fPSA/tPSA ratio, Prostate Health Index, and glycosylation patterns of free PSA in patients with benign prostatic hyperplasia pharmacotherapy
by: Michal Jirásko, et al.
Published: (2024)

Assessing state‐of‐the‐art online large language models for patient education regarding prostatitis
by: Pengfei Zhang, et al.
Published: (2024)

Modern predictors and management of incidental prostate cancer at holmium enucleation of prostate
by: Eric V. Li, et al.
Published: (2024)

Does larger prostate size provide protection for cancer specific outcomes in localized prostate cancer
by: Zain Abedali, et al.
Published: (2024)

Cutibacterium acnes invades prostate epithelial cells to induce BRCAness as a possible pathogen of prostate cancer
by: Shingo Ashida, et al.
Published: (2024)

Diagnosis and management of neuroendocrine prostate cancer
by: Ivan de Kouchkovsky, et al.
Published: (2024)

Effects of oral administration of nonselective Trk inhibitor on bladder overactivity in rodent models of prostatic inflammation
by: Taro Igarashi, et al.
Published: (2024)

Incidence and risk factors of prostate cancer among the Northern and Eastern parts of the United Arab Emirates population
by: Jian Wang, et al.
Published: (2024)

Other‐cause mortality in incidental prostate cancer
by: Francesco Di Bello, et al.
Published: (2024)

Influence of microbiome in intraprostatic inflammation and prostate cancer
by: Pranav Prakash, et al.
Published: (2024)

Consistent predictive ability of prostate‐specific antigen density prediction model for clinically significant prostate cancer across age strata
by: Kamil Malshy, et al.
Published: (2024)

Machine learning and explainable artificial intelligence to predict pathologic stage in men with localized prostate cancer
by: Hemal Semwal, et al.
Published: (2024)

Analysis of three primary prostatic sarcoma cases and literature review
by: Yirui Wei, et al.
Published: (2024)

FOXA1 regulates ribosomal RNA transcription in prostate cancer
by: Tianwei Jia, et al.
Published: (2024)

Translation and validation of a lifestyle questionnaire related to prostate cancer
by: Reyhane Karegar‐Niavol, et al.
Published: (2024)

Key learnings from concordant systematic biopsies in prostate‐specific membrane antigen positron emission tomography/computed tomography‐guided prostate biopsies: Enhancing targeting accuracy
by: Thomas Büttner, et al.
Published: (2024)

The role of gut microbiota involved in prostate microenvironment and symptoms improvement in chronic prostatitis/chronic pelvic pain syndrome patients treated with low‐intensity extracorporeal shock wave
by: Xiangbin Kong, et al.
Published: (2024)

Investigation of pelvic floor influence on prostate displacement in image‐guided radiotherapy
by: Hongbo Chai, et al.
Published: (2024)

Three‐dimensional ultrastructural and anatomical analysis of prostatic neuroendocrine cells in mice
by: Kei‐Ichiro Uemura, et al.
Published: (2024)

Ejaculatory and erectile function outcomes following holmium laser enucleation of the prostate
by: Chinade Roper, et al.
Published: (2024)

Retrospective analysis of the learning curve in perineal robot‐assisted prostate biopsy
by: Ruth Himmelsbach, et al.
Published: (2024)

The detection rate for prostate cancer in systematic and targeted prostate biopsy in biopsy‐naive patients, according to the localization of the lesion at the mpMRI: A single‐center retrospective observational study
by: Matteo Massanova, et al.
Published: (2024)

Size and SUVmax define the contribution of nodal metastases to PSA in oligorecurrent prostate cancer
by: Fabian Falkenbach, et al.
Published: (2024)

Cumulative cancer locations on prostate biopsy and active surveillance outcomes in the MRI era
by: Sean A. Fletcher, et al.
Published: (2024)

Lower urinary tract symptoms in elderly men: Considerations for prostate cancer testing
by: Stephen Schmit, et al.
Published: (2024)

L1CAM mediates neuroendocrine phenotype acquisition in prostate cancer cells
by: Chia‐Ling Hsieh, et al.
Published: (2024)

Testosterone bounce predicts favorable prognoses for prostate cancer patients treated with degarelix
by: Shuhei Kamada, et al.
Published: (2024)

Development and validation of an imageless machine‐learning algorithm for the initial screening of prostate cancer
by: Nicolas Martelin, et al.
Published: (2024)

Co‐targeting SKP2 and KDM5B inhibits prostate cancer progression by abrogating AKT signaling with induction of senescence and apoptosis
by: LaKendria K. Brown, et al.
Published: (2024)

Distribution of neurovascular structures within the prostate gland and their relationship to complications after radical prostatectomy
by: Ghazi Alanazi, et al.
Published: (2024)

Outcomes of 10 years of PSA screening for prostate cancer in Norwegian men with Lynch syndrome
by: Eli Marie Grindedal, et al.
Published: (2024)

Sodium butyrate alleviates experimental autoimmune prostatitis by inhibiting oxidative stress and NLRP3 inflammasome activation via the Nrf2/HO‐1 pathway
by: Xiaoliang Hua, et al.
Published: (2024)

Real‐world study: Impact of multidisciplinary management of apalutamide‐associated adverse events in prostate cancer
by: Julián Córdoba Sánchez, et al.
Published: (2024)

Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone‐sensitive prostate cancer: A multicenter study
by: Takafumi Yanagisawa, et al.
Published: (2024)

PIK3/Akt/mTOR pathway alterations in metastatic castration‐sensitive prostate cancer
by: Philip Sutera, et al.
Published: (2024)

An orthotopic prostate cancer model for new treatment development using syngeneic or patient‐derived tumors
by: Naz Chaudary, et al.
Published: (2024)

Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker of proliferation Ki67
by: Fengnian Zhao, et al.
Published: (2024)